– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...

SELLAS Life Sciences Group, Inc. announced positive overall survival results from their ongoing Phase 2 trial of SLS009 (tambiciclib) in patients with relapsed/refractory acute myeloid leukemia (AML), ...

Decitabine often is given to older patients with AML or MDS because it is less toxic than standard chemotherapies. But fewer than half of patients who get the drug achieve an initial remission, so the ...

A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Disruptions in transcriptional regulation during hematopoiesis can lead to abnormal hematopoietic differentiation and the development of leukemia. Understanding the underlying mechanisms of disease ...